Advances in endometrial cancer protein biomarkers for use in the clinic

Elena Martinez-Garcia, Carlos Lopez-Gil, Irene Campoy, Julia Vallve, Eva Coll, Silvia Cabrera, Santiago Ramon Y Cajal, Xavier Matias-Guiu, Jan Van Oostrum, Jaume Reventos, Antonio Gil-Moreno, Eva Colas

Research output: Contribution to journalReview articleResearchpeer-review

9 Citations (Scopus)


© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Endometrial cancer (EC) is the fourth most common cancer in women in developed countries. The identification of sensitive and specific biomarkers to improve early detection of EC is crucial for an appropriate management of this disease, in which 30% of patients are diagnosed only at advanced stages, which is associated with high levels of morbidity and mortality. Despite major efforts and investments made to identify EC biomarkers, no protein has yet reached the stage of clinical application. Areas covered: This review gathers the numerous candidate biomarkers for EC diagnosis proposed in proteomic studies published from 1978 to 2017. Additionally, we summarize limitations associated with the proteomic technologies and study designs employed in those articles. Finally, we address new perspectives in EC biomarker research, including the comprehensive knowledge of previously suggested candidate biomarkers in conjunction with novel mass spectrometry-based proteomic technologies with enhanced sensitivity and specificity not yet applied to EC studies and a directed clinical perspective in the study design. Expert commentary: These ingredients could be the recipe to accelerate the application of protein biomarkers in the clinic.
Original languageEnglish
Pages (from-to)81-99
JournalExpert Review of Proteomics
Issue number1
Publication statusPublished - 2 Jan 2018


  • Biomarker
  • biomarker pipeline
  • bodyfluid
  • diagnosis
  • endometrial cancer
  • liquid biopsy
  • mass spectrometry
  • proteomics
  • study design

Fingerprint Dive into the research topics of 'Advances in endometrial cancer protein biomarkers for use in the clinic'. Together they form a unique fingerprint.

Cite this